What is CTXR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CTXR?

P/E (TTM) is n/a and 52-week range is $0.37 to $1.98 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CTXR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CTXR?

The company profile lists revenue (TTM) near $7M, net income (TTM) near -$59M, EPS (TTM) near -$2.13 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Citius Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cranford, New Jersey, US, 27.4M shares outstanding, ISIN US17322U3068 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Citius Pharmaceuticals Inc

$CTXR

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 23 full-time employees. The company went IPO on 2017-08-03. The firm's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The firm is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Employees

Website

www.citiuspharma.com/

IPO

2017-08-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US17322U3068

Headquarters

Cranford, New Jersey, US

Shares outstanding

27.4M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

4.94%

Browse other companiesFree AI scores and summaries for more stocks